Tumor Necrosis Factor Induces Obliterative Pulmonary Vascular Disease in a Novel Model of Connective Tissue Disease–Associated Pulmonary Arterial Hypertension
Autor: | Benjamin D. Korman, Marc Nuzzo, Edward M. Schwarz, Maria de la Luz Garcia-Hernandez, Min Yee, Michael A. O'Reilly, Nelson Huertas, Pamelia N. Slattery, Homaira Rahimi, Roberta Goncalves Marangoni, Emily Wu, Craig N. Morrell, R. James White, Christopher T. Ritchlin, Richard D. Bell, Stacey Duemmel |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Pathology medicine.medical_specialty Heart Ventricles Immunology Mice Transgenic 030204 cardiovascular system & hematology Article 03 medical and health sciences 0302 clinical medicine Rheumatology Von Willebrand factor Animals Immunology and Allergy Medicine Connective Tissue Diseases Lung Associated Pulmonary Arterial Hypertension Cardiopulmonary disease Pulmonary Arterial Hypertension Hypertrophy Right Ventricular biology Tumor Necrosis Factor-alpha business.industry Vascular disease Endothelial Cells X-Ray Microtomography medicine.disease Connective tissue disease Disease Models Animal 030104 developmental biology Blood pressure medicine.anatomical_structure Heart catheterization biology.protein Bone marrow business |
Zdroj: | Arthritis Rheumatol |
ISSN: | 2326-5205 2326-5191 |
DOI: | 10.1002/art.41309 |
Popis: | OBJECTIVE Connective tissue disease (CTD)-associated pulmonary arterial hypertension (PAH) is the second most common etiology of PAH and carries a poor prognosis. Recently, it has been shown that female human tumor necrosis factor (TNF)-transgenic (Tg) mice die of cardiopulmonary disease by 6 months of age. This study was undertaken to characterize this pathophysiology and assess its potential as a novel model of CTD-PAH. METHODS Histologic analysis was performed on TNF-Tg and wild-type (WT) mice to characterize pulmonary vascular and right ventricular (RV) pathology (n = 40 [4-5 mice per group per time point]). Mice underwent right-sided heart catheterization (n = 29) and micro-computed tomographic angiography (n = 8) to assess vascular disease. Bone marrow chimeric mice (n = 12), and anti-TNF-treated mice versus placebo-treated mice (n = 12), were assessed. RNA sequencing was performed on mouse lung tissue (n = 6). RESULTS TNF-Tg mice displayed a pulmonary vasculopathy marked by collagen deposition (P < 0.001) and vascular occlusion (P < 0.001) with associated RV hypertrophy (P < 0.001) and severely increased RV systolic pressure (mean ± SD 75.1 ± 19.3 mm Hg versus 26.7 ± 1.7 mm Hg in WT animals; P < 0.0001). TNF-Tg mice had increased α-smooth muscle actin (α-SMA) staining, which corresponded to proliferation and loss of von Willebrand factor (vWF)-positive endothelial cells (P < 0.01). There was an increase in α-SMA-positive, vWF-positive cells (P < 0.01), implicating endothelial-mesenchymal transition. Bone marrow chimera experiments revealed that mesenchymal but not bone marrow-derived cells are necessary to drive this process. Treatment with anti-TNF therapy halted the progression of disease. This pathology closely mimics human CTD-PAH, in which patient lungs demonstrate increased TNF signaling and significant similarities in genomic pathway dysregulation. CONCLUSION The TNF-Tg mouse represents a novel model of CTD-PAH, recapitulates key disease features, and can serve as a valuable tool for discovery and assessment of therapeutics. |
Databáze: | OpenAIRE |
Externí odkaz: |